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ical outcome.Objectives: The purpose of the present randomized controlled clinical trial
was to compare the use of donkey milk–derived fortifier (DF) with
commercial bovine milk–derived fortifier (BF) in very preterm or very-
low-birth-weight newborns, in terms of feeding tolerance.
Methods: This trial included 156 newborns born at <32 weeks of
gestational age and/or with a birth weight 1500 g. Newborns were
randomized 1:1 to receive enteral feeding with either a BF-arm, or a
new, DF-arm for 21 days. The fortification protocol was the same for
both study arms, and the 2 diets were designed to be isoproteic and
isocaloric. Feeding tolerance was assessed by a standardized protocol.
Results: The risk of feeding intolerance tended to be lower in DF-arm than
in BF-arm, with a relative risk reduction of 0.63 (95% confidence interval:
0.29, þ0.90). The mean number of episodes per newborn of feeding
intolerance and feeding interruptions (any duration) were consistently lower
in the DF-arm than in the BF-arm. Episodes of bilious gastric residuals and
vomiting were significantly lower in the DF-arm. Time needed to reach full
enteral feeding (150 mL  kg1  day1) and daily weight increase between
the first day of exclusive enteral feeding (ie, without administering
intravenous fluids) and discharge were similar in the BF- and DF-arms.
Conclusions: These results suggest that DF improve feeding tolerance when
compared with standard bovine-derived fortifiers, with a similar auxological
outcome.
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fortifier, very low birth weight infants(JPGN 2019;68: 116–123)
ery preterm (gestational age <32 weeks) and very-low-birth-
weight (VLBW, ie, <1500 g) newborns currently representV
the majority of patients admitted to neonatal intensive care units(NICU) (1). Improvements in perinatal care have led to an increased
survival rate in these newborns, which has offered new insights into
their outcome and their health status in adulthood.
Nutrition is fundamental to neonatal survival and short-term
outcomes, but it also has long-term consequences on quality of life
in very preterm and VLBW newborns. Indeed, these newborns
require adequate qualitative and quantitative nutrition, particularly
in terms of protein intake, the lack of which is the main cause of
postnatal growth deficits (2). Human milk is the recommended foody Compagnia di San Paolo, Italy, Award n. 2539 to
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nutritional requirements of preterm newborns (5,6), it is supple-
mented with additional nutrients (7,8).
Fortification of human milk still represents a significant
challenge (9–11), as concerns have been raised regarding
fortification strategies and the composition of fortifiers. Indi-
vidualized fortification is the current recommended strategy
(12,13), and fortifiers must be composed of simple, high-
quality, well-tolerated nutritional supplements. Recently, human
milk–based fortifiers have been proposed, but their utilization
is limited by high costs and ethical issues. Moreover, there is no
strong evidence that human milk–based fortifiers in otherwise
exclusively human milk–fed preterm infants affect important
outcomes. (14).
Based on its physiochemical properties, milk from mono-
gastric animals has been suggested to be more suitable than bovine
milk for human nutrition (15). Donkey milk showed biological
effects comparable with those elicited by human milk (16,17). Our
hypothesis is that feeding very preterm and VLBW newborns with
human milk supplemented with donkey milk–derived fortifiers
(DFs) will improve feeding tolerance. Thus, the present trial
compared the use of DF and commercial bovine milk–derived
fortifier (BF) in very preterm and VLBW newborns, in terms of
feeding tolerance and short-term auxological outcomes.
METHODS
This study was performed in the NICU of Turin University. It
was approved by Ethics Committee (AN: 0025847, 27/05/2014)
and registered (http://www.isrctn.com/ISRCTN70022881,
ISRCTN70022881) after the trial starting date. The study protocol
was evaluated by JPGN Editorial Office. Recruitment period was
27/11/2014 to 22/12/2016. Written informed consent was obtained
from the parents of all included newborns before enrollment.
Study Population
The inclusion criteria were gestational age <32 weeks and/
or birth weight 1500 g, exclusive feeding with human milk
(own mother’s milk or donor milk), and enteral feeding
80mL  kg1  day1 within the first 4 weeks of life. Newborns
with severe gastrointestinal pathologies (necrotizing enterocolitis,
colostomy, intestinal obstruction, symptoms of peritonitis, pres-
ence of blood in the feces), chromosomal abnormalities or major
malformations, hereditary metabolic diseases, intravascular
disseminated coagulopathy, shock, patent ductus arteriosus
(PDA) requiring medical care or surgery at the time of randomi-
zation, and severe renal failure (serum creatinine >2mg/dL)
were excluded.
Study Design
Eligible newborns were randomly allocated 1:1 into 2 arms in
accordance with a list generated by a data step written in SAS (18)
language: the BF-arm and the DF-arm. In the BF-arm, a bovine
milk–derived commercial multicomponent fortifier (FM85, Nestle´)
and a bovine milk–derived protein concentrate (Protifar, Nutricia,
Utrecht, The Netherlands) were used. In the DF-arm a donkey
milk–derived multicomponent fortifier and donkey milk–derived
protein concentrate were used (FortiLat, Torino, Italy). The DF is
not commercially available and was produced according to current
EU legislation on food for special medical purposes.
All newborns received enteral feeding according to a regimen
of adjustable fortification, based on blood urea nitrogen determi-
nation, for 21 days (19,20). The intervention started when thewww.jpgn.orginfants were able to tolerate a volume of 80mL  kg  day
(randomization time) and, according to study protocol, was planned
to last 21 days; the intervention was suspended at discharge from the
hospital for any reason (transfer, death, discharge home).
Please refer to our previous article (21) for a detailed
description of the methodology used in the study. Because the
protein concentration and energy content of bovine milk–derived
products differ from those of donkey milk–derived products, the
amounts of powder required to obtain the same level of fortification
were different. Moreover, because the same nurses were in charge of
both the preparation and administration of meals and the evaluation
of feeding tolerance, this study must be regarded as an open-label
trial. Increases in the quantity of milk given during enteral feeding
were strictly regulated according to the feeding protocol adopted in
the NICU, based on the evaluation of signs of feeding intolerance.
Data on necrotizing enterocolitis that occurred after randomization,
PDA, sepsis, mortality, hospital stay duration, intraventricular
hemorrhage, and retinopathy of prematurity (defined according
to the Vermont Oxford Network) (22) were collected from
hospital records.
Babies were discharged from the hospital when they met all
following criteria: satisfactory weight gain while receiving full oral
feeding, maintenance of adequate thermal stability, and resolution
of acute medical conditions.
Outcome Measures of Feeding Tolerance
Primary Endpoint
Primary endpoint includes death, necrotizing enterocolitis, or
at least 1 episode of feeding intolerance, defined as interruption of
enteral feeding for at least 8 consecutive hours during the
observation period.
Secondary Endpoints
Secondary endpoints include number of episodes of feeding
intolerance, feeding interruption (any duration), bilious gastric
residuals, vomiting, and total hours of enteral feeding interruption.
Time required to reach full enteral feeding
(150 mL  kg1  day1) and daily weight gain (weight-D standard
deviation score (DSDS)/days) from the first day of exclusive enteral
feeding (without administering intravenous fluids) until discharge
were also evaluated.
Study Size
The evaluation of the previous year’s hospital records, car-
ried out before the start of the present study, revealed that approxi-
mately 45% of very preterm or VLBW newborns admitted to the
NICU had at least 1 episode of feeding intolerance (primary
endpoint). A 25% reduction in the frequency of the primary
endpoint was regarded as the minimum clinically important differ-
ence; under these assumptions, 62 newborns per arm had to be
recruited to ensure an 80% study power, given a risk of type I error
at the usual level of 5%. However, the occurrence of the primary
endpoint was much lower than that assumed in the protocol, and no
adverse effect of FortiLat was observed. Because the occurrence of
primary endpoint in our study population resulted to be much lower
than that assumed in the protocol, and no adverse effect was
observed, when the planned study size was achieved, it was decided
to continue the enrollment until the stock of FortiLat ran out. For
this reason, we present information on the planned study with the
initial 62 newborns per arm, and the extended study, with the
additional recruitment. A further randomization list was generated
for the extension of the study.117
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The analysis was performed on 2 populations: A
rFIG
for
11ll randomized subjects (ARS) population, which included all
andomized newborns.URE 1. Diagram of the enrollment, randomization, and study alloc
tifier.
8 P
oatioer-protocol (PP) population, which included only newborns
bserved for 21 days in our hospital, and that actually received
donkey milk or bovine fortifier according to the protocol,
excluding, consequently, the babies transferred to other hospitals
or discharged home before 21 days of observation.n. BF¼bovine milk–derived fortifier; DF¼donkey milk–derived
www.jpgn.org
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in the PP population. In the ARS population, the analysis (primary
analysis) was performed in accordance with the intention-to-treat
approach: failure included all the conditions that cannot be
defined success, that is, occurrence of necrotizing enterocolitis,
at least 1 episode of feeding intolerance, death, or transfer to
another hospital before day 21 of observation. Subjects in the
ARS population who were discharged home before the 21st day
were considered successes, under the assumption that they main-
tained good tolerance at home. In the PP population, from which
subjects transferred to another hospital or discharged before the
21st day are excluded, the occurrence of death, necrotizing
enterocolitis, and at least 1 episode of feeding intolerance were
regarded as failure.
The difference in the outcome between the 2 study arms was
tested with the Fisher exact test. The risk of recurrent episodes of
feeding intolerance (interruption of enteral feeding for at leastTABLE 1. Maternal and neonatal characteristics, clinical condition at rando
period
BF-arm (n¼
Maternal characteristics
Pregravidic BMI, kg/m2 Mean (SD) 23.7 (4.53)
Weight gain in pregnancy, kg Mean (SD) 9.0 (6.02)
Age, y Median (IQR) 33.5 (30–3
Chronic diabetes n (%) 0 (0.0)
Chronic hypertension n (%) 3 (4.8)
Gestational diabetes n (%) 10 (16.1)
Gestational hypertension n (%) 18 (29.0)
Caesarean delivery n (%) 50 (80.6)
Prelabor rupture of membranes n (%) 17 (27.4)
Assisted reproductive technology n (%) 15 (24.2)
Neonatal characteristics
Boys n (%) 29 (46.8)
Singletons n (%) 35 (56.5)
Firstborn n (%) 40 (64.5)
Gestational age <32 wk

n (%) 50 (80.6)
VLBW (birth weight 1500 g)y n (%) 57 (91.9)
Small for gestational agez n (%) 16 (25.8)
Weight, g Mean (SD) 1166 (297.3
Weight (SDS) Mean (SD) 0.36 (1.122
RDS n (%) 53 (85.5)
Age at randomization, days Median (IQR) 9.0 (6–17
Age at start of intervention, days Median (IQR) 11.5 (8–17
Intraventricular hemorrhage n (%) 5 (8.1)
Recovered patent ductus arteriosus n (%) 20 (29.4)
Clinical outcome and morbidities
Length of hospital stay§ Median (IQR) 45 (32–6
Transferred to other hospital n (%) 6 (9.7)
Dead before discharge n (%) 1 (1.6)
Steroids therapy n (%) 1 (1.6)
Early sepsis n (%) 3 (4.8)
Late sepsis n (%) 4 (6.5)
Necrotizing enterocolitis n (%) 1 (1.6)
BF¼ bovine milk–derived fortifier; BMI¼ body mass index; DF¼ donkey m
syndrome; SD¼ standard deviation; SDS¼ standard deviation score; VLBW¼
Regardless of birth weight.
yRegardless of gestational age at birth.
zBirth weight below the 10th centile of Italian Neonatal Study (INeS) charts
§Computed on babies discharged to home.
www.jpgn.org8 hours) in the 2 arms was estimated on the ARS population with
the Andersen and Gill Cox’s model for recurrent processes (23).
The analysis of secondary endpoints, because time-depen-
dent, was carried out on PP population, resorting to generalized
linear models (24): the number of episodes of feeding intolerance,
feeding interruptions (any duration), bilious gastric residuals, and
vomiting occurred during the observation were modeled as a
Poisson variable; total hours of enteral feeding interruption were
modeled, after log-transformation, as normal variables. Median
time required to reach full enteral feeding was estimated on the
ARS population according to Kaplan and Meyer (25). Body weight
was expressed as SDS, with respect to Italian Neonatal Study
(INeS) charts (26). To evaluate differences in growth between
the 2 arms, weight gain was expressed as weight-DSDS/days, that
is, the mean daily weight-SDS variation between SDS on the first
day of exclusive enteral feeding and discharge. In this analysis, only
babies discharged home were considered.mization, and clinical outcome and morbidities during the observation
Planned study Extended study
62) DF-arm (n¼ 62) BF-arm (n¼ 79) DF-arm (n¼ 77)
23.6 (5.70) 23.4 (4.47) 24.0 (5.96)
8.2 (6.14) 8.7 (6.00) 8.8 (5.94)
8) 34.5 (30–39) 34 (30–38) 34 (30–39)
1 (1.6) 0 (0.0) 1 (1.3)
2 (3.2) 3 (3.8) 3 (3.9)
11 (17.7) 11 (13.9) 14 (18.2)
11 (18.0) 22 (27.8) 12 (15.8)
46 (74.2) 58 (73.4) 60 (77.9)
15 (24.2) 23 (29.1) 17 (22.1)
12 (19.4) 19 (24.1) 13 (16.9)
31 (50.0) 36 (45.6) 37 (48.1)
40 (64.5) 47 (59.5) 46 (59.7)
39 (62.9) 51 (64.6) 50 (64.9)
48 (77.4) 64 (81.0) 55 (71.4)
53 (85.5) 70 (88.6) 65 (84.4)
20 (32.3) 19 (24.4) 27 (35.1)
) 1196 (315.7) 1161 (310.3) 1214 (311.5)
) 0.64 (1.165) 0.35 (1.120) 0.74 (1.162)
54 (87.1) 69 (87.3) 67 (87.0)
) 8.5 (5–14) 9.0 (6–17) 8.0 (5–14)
) 10.5 (7–17) 12.0 (8–18) 11.0 (7–17)
2 (3.2) 8 (10.1) 3 (3.9)
11 (16.2) 26 (38.5) 11 (16.2)
3) 39.5 (29.5–63) 45.5 (32–63) 38 (28–56)
5 (8.1) 7 (8.9) 5 (6.5)
1 (1.6) 1 (1.3) 1 (1.3)
1 (1.6) 1 (1.3) 1 (1.3)
1 (1.6) 4 (5.1) 1 (1.3)
3 (4.8) 5 (6.3) 3 (3.9)
1 (1.6) 1 (1.3) 1 (1.3)
ilk–derived fortifier; IQR¼ interquartile range; RDS¼ respiratory distress
very-low-birth weight.
[26].
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models (18).
RESULTS
The ARS population consisted of 124 newborns enrolled in
the planned study (BF-arm: n¼ 62; DF-arm: n¼ 62). During the
extended study 32 more newborns were enrolled, for a total of 156
babies (BF-arm: n¼ 79, DF-arm: n¼ 77) (Fig. 1). The PP popula-
tion (patients that completed 21 days of observation) was made up
of 89 newborns (BF-arm: 44, DF-arm: 45) in the planned study and
111 (BF-arm: 57, DF-arm: 54) in the extended study. No babies
switched from one arm to the other.
Table 1 shows the characteristics of mothers and neonates
included in the planned and extended study before enrollment and
clinical outcome and morbidities that occurred during the observa-
tion period. In the table, PDA refers to a condition from which the
newborn recovered before randomization. The median time lag
between the random assignment of subjects to either arms and the
actual start of the intervention did not exceed 3 days. One baby per
arm died following necrotizing enterocolitis.
Primary Endpoint
The number of failures and successes observed in the 2 arms
for the planned and the extended study is reported in Supplementary
Table 1 (top) (Supplemental Digital Content, http://links.lww.com/
MPG/B499). Risk of failure in the planned study tended to be lower
in the DF- than in the BF-arm, with a relative risk reduction of 0.40
(95% confidence interval [CI]: 0.27, þ0.72; Fisher exact test:
P¼ 0.256) in the ARS and 0.63 (95% CI: 0.29, þ0.90; P¼ 0.118)
in the PP population (Fig. 2, left). Results were similar in theFIGURE 2. Primary endpoint: risk of failure in the 2 arms and relative risk
subjects; PP¼per-protocol.
120extended study, with relative risk reductions of 0.46 (95% CI:
0.09, þ0.73; P¼ 0.100) in the ARS and 0.58 (95% CI: 0.27,
þ0.86; P¼ 0.153) in the PP population (Fig. 2, right).
Secondary Endpoints
The number of episodes of feeding intolerance, feeding
interruptions (any duration), bilious gastric residuals, and vomiting
for the planned and extended study observed in the PP population is
reported in Supplementary Table 1 (bottom) (Supplemental Digital
Content, http://links.lww.com/MPG/B499). During the observation
period, the mean number of episodes per newborn of these second-
ary endpoints was consistently lower in the DF- than in the BF-arm.
Indeed, the difference between the BF- and the DF-arm ranged from
0.09 to 0.31 in the planned study (Fig. 3, left), and from 0.15 to 0.35
in the extended study (Fig. 3, right). In the extended study, the
difference between the arms was statistically significant as regards
the number of episodes of bilious gastric residuals (P¼ 0.009) and
vomiting (P¼ 0.041).
The hazard ratio of recurrent feeding intolerance epi-
sodes (DF-arm vs BF-arm), estimated in the ARS population
using Anderson and Gill Cox’s model for recurrent processes,
was 0.53 (95% CI: 0.20, 1.44; P¼ 0.215) in the planned study,
and 0.40 (95% CI: 0.17, 0.95; P¼ 0.038) in the extended
study.
The median time to achieve full enteral feeding in the BF-
and DF-arms was 19 days (95% CI: 15, 23), both in the planned and
in the extended study. The total number of hours of feeding
interruptions did not differ significantly between the 2 arms, neither
in the planned study (BF-arm: 1.28; 95% CI: 0.50, 2.49 and DF-
arm: 0.68; 95% CI: 0.10, 1.55; P¼ 0.304) nor in the extended studyreduction (RRR), and 95% confidence intervals. ARS¼ all randomized
www.jpgn.org
FIGURE 3. Secondary endpoints (on PP population): means, mean differences, and 95% confidence intervals.
JPGN  Volume 68, Number 1, January 2019 A Novel Donkey Milk–derived Human Milk Fortifier
www.jpgn.org 121
Bertino et al JPGN  Volume 68, Number 1, January 2019(BF-arm: 1.15; 95% CI: 0.49, 2.12 and DF-arm: 0.66; 95% CI: 0.14,
1.44; P¼ 0.340).
Mean daily weight increase between the first day of exclu-
sive enteral feeding and discharge (expressed as DSDS/day) did not
differ between the BF-arm (0.013; 95% CI: 0.018, 0.009) and
the DF-arm (0.012; 95% CI: 0.016, 0.008) in the planned
study. Similar results were observed in the extended study (BF-arm:
0.012; 95% CI: 0.016, 0.008; DF-arm: 0.013; 95% CI:
0.018, 0.008).DISCUSSION
The aim of the study was to assess the effects of a donkey
milk–derived human milk fortifier on feeding tolerance among
very preterm (gestational age <32 weeks) and VLBW (1500 g)
newborns. To the best of our knowledge, our trial is the first to
investigate the use of a DF for the nutrition of very preterm and
VLBW newborns. All newborns (both the BF-arm and the DF-arm)
received human milk exclusively (raw own mother’s milk or
pasteurized donor milk), without any preterm bovine formula
supplementation. In contrast, Sullivan et al (27) included
subjects receiving preterm formula in the group supplemented
with the bovine fortifier in their comparison of a human milk–
based and bovine milk–based fortifier, which represents a
confounding variable.
In our study, we observed a lower number of failures
(necrotizing enterocolitis, at least 1 episode of feeding intolerance,
or death) and a lower hazard of feeding intolerance episodes in the
DF-arm, both in the planned and in the extended study, in ARS and
in PP population. The mean number of episodes per newborn of
feeding intolerance, feeding interruptions (any duration), bilious
gastric residuals, and vomiting during the observation period was
consistently lower in DF-arm, both in the planned study and in the
extended study. Overall, these results suggest the favorable effect of
the donkey milk fortifier on feeding tolerance, which could not be
demonstrated due to the unexpected lack of power of our study.
Actually, our study was planned under the assumption that the
occurrence of failures (necrotizing enterocolitis, at least 1 episode
of feeding intolerance, or death) in the control arm (BF-arm) was
45%, whereas during the trial it was only 24%. This could be due to
the so-called Hawthorne effect (28,29), that is, to the fact that the
behavior of clinical staff may be affected and improved when a trial
is conducted in a clinical setting. Because of the lower occurrence of
failures, the statistical power to detect a decrease from 24% to 11%
(ie, the same relative decrease in failure occurrence assumed in the
protocol), was only 38% (about half of the prefixed 80%) in the
planned study and 48% in the extended study. Under these condi-
tions, it would have been necessary to enroll 148 subjects per arm to
achieve an 80% power.
Overall, a better tolerance of DFs emerged. We speculate that
the quality of donkey milk protein could be responsible of this
result, the 2 diets being isoproteic and isocaloric. Weight gain was
similar in BF- and DF-arms, suggesting that differences in tolerance
do not affect short-term growth, at least under the conditions on
which this trial was carried out, where a parenteral intake was
provided in case of episodes of enteral feeding intolerance and
suspension. For this reason, a similar total nutritional intake was
provided in all subjects. At present, commercially available for-
tifiers are bovine milk derived, with a protein composition that is
very different from that of human milk. Bovine milk whey proteins
contained in the fortifier used in this study strongly differ from
human milk counterparts in term of relative abundance and primary
structure (30). The intake of bovine milk protein in the first months
of life has raised concerns because of its association with allergies
(31). Furthermore, bovine milk has been reported as a possible122trigger of intestinal inflammation in preterm neonates (32,33).
Previously, we found that the protein and lipid fractions in donkey
milk are similar to those in human milk (30,34). We also observed
that donkey milk was well tolerated in a group of children with
highly problematic cow’s milk allergies (35). Moreover, it has
recently been demonstrated in murine models that a supplementa-
tion of the basal diet with donkey milk decreases the accumulation
of body lipids and affects glucose and lipid metabolism in a manner
more similar to human than to bovine milk. These biological effects
are comparable to those elicited by human milk (16,17). Based on
the above-mentioned studies and the results obtained in the present
trial, it can be hypothesized that donkey milk is more suitable than
bovine milk as an ingredient in human milk fortifier for very
preterm and VLBW newborns.
For a more comprehensive evaluation of the results, we
should consider that the 2 arms slightly differed: a higher number
of newborns developed PDA in the BF-arm before randomization
(and PDA at the time of randomization was an exclusion criterion),
small for gestational age (SGA) newborns were more frequent in
the DF-arm, whereas VLBW newborns were more frequent in the
BF-arm.
The presence of symptomatic PDA may theoretically impair
feeding tolerance because of the impact on blood flow to vital
organs (36,37), but at time of randomization this condition had been
resolved. SGA newborns are at higher risk for intestinal distur-
bances, ranging from temporary enteral feeding intolerance to
necrotizing enterocolitis. In our study, the best tolerance was
observed in the DF-arm, in which SGA subjects, who were at
major risk of feeding difficulties, were more numerous.
A limitation of this trial is that it was designed as an open-
label randomized clinical trial, because the nurses in charge of the
preparation of meals were also in charge of evaluating signs of
feeding tolerance. The nurses, however, involved in the trial should
stick to a strict protocol to reduce their discretion in the evaluation
of signs of feeding intolerance.
To conclude, the new DF was well tolerated in our popula-
tion. The results of this trial may constitute a sound basis on which
to plan a further trial with enough power to confirm the higher
tolerability of the DF and open new perspectives for the production
of human milk fortifiers other than those derived from bovine milk.
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